oru.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Outcome measures in coeliac disease trials: the Tampere recommendations
Örebro universitet, Institutionen för medicinska vetenskaper. Region Örebro län. Department of Medical epidemiology and Biostatistics, Karolinska institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro, Sweden.ORCID-id: 0000-0003-1024-5602
Coeliac Center at Department of Medicine and Surgery, Scuola Medica Salernitana, University of Salerno, Salerno, Italy.ORCID-id: 0000-0002-7426-1145
Celiac Disease Center at Columbia University, New York, USA.
Celiac Disease Research Center, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland; Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
Vise andre og tillknytning
2018 (engelsk)Inngår i: Gut, ISSN 0017-5749, E-ISSN 1468-3288, Vol. 67, nr 8, s. 1410-1424Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Objective: A gluten-free diet is the only treatment option of coeliac disease, but recently an increasing number of trials have begun to explore alternative treatment strategies. We aimed to review the literature on coeliac disease therapeutic trials and issue recommendations for outcome measures.

Design: Based on a literature review of 10 062 references, we (17 researchers and 2 patient representatives from 10 countries) reviewed the use and suitability of both clinical and non-clinical outcome measures. We then made expert-based recommendations for use of these outcomes in coeliac disease trials and identified areas where research is needed.

Results: We comment on the use of histology, serology, clinical outcome assessment (including patient-reported outcomes), quality of life and immunological tools including gluten immunogenic peptides for trials in coeliac disease.

Conclusion: Careful evaluation and reporting of outcome measures will increase transparency and comparability of coeliac disease therapeutic trials, and will benefit patients, healthcare and the pharmaceutical industry.

sted, utgiver, år, opplag, sider
BMJ Publishing Group Ltd, 2018. Vol. 67, nr 8, s. 1410-1424
HSV kategori
Identifikatorer
URN: urn:nbn:se:oru:diva-68770DOI: 10.1136/gutjnl-2017-314853ISI: 000442465300008PubMedID: 29440464Scopus ID: 2-s2.0-85047308664OAI: oai:DiVA.org:oru-68770DiVA, id: diva2:1246264
Forskningsfinansiär
Swedish Research Council, 522-2A09-195Swedish Society of Medicine
Merknad

Funding Agencies:

German Research Foundation (DFG)  

Ministry of Research and Development (BMBF)  

Leibniz Foundation  

Biocard  

Simtomax  

Academy of Finland  

Competitive Research Funding of the Tampere University Hospital  

Sigrid Juselius Foundation   Hungarian Research Fund  NKFI 120392 

Competitive State Research Financing of the Tampere University Hospital  9U038 

Tilgjengelig fra: 2018-09-07 Laget: 2018-09-07 Sist oppdatert: 2018-09-07bibliografisk kontrollert

Open Access i DiVA

Fulltekst mangler i DiVA

Andre lenker

Forlagets fulltekstPubMedScopus

Personposter BETA

Ludvigsson, Jonas F.

Søk i DiVA

Av forfatter/redaktør
Ludvigsson, Jonas F.Ciacci, Carolina
Av organisasjonen
I samme tidsskrift
Gut

Søk utenfor DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 128 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf